{
  "doc_id": "8718d1412b12479293af4793a54dac41d06fdf67f55eac6276259594a243e825",
  "chunk_entities": [
    {
      "chunk_id": "10f76094d99e435851589332639c372f",
      "entities": [
        {
          "entity_type": "Disease",
          "entity_name": "addiction",
          "context": "Neurobiology of addiction"
        }
      ]
    },
    {
      "chunk_id": "bc0f72cfaed6c9800a276890b64133f7",
      "entities": [
        {
          "entity_type": "Disease",
          "entity_name": "substance use disorders",
          "context": "individuals who have substance use disorders"
        },
        {
          "entity_type": "Disease",
          "entity_name": "chronic addiction",
          "context": "drug intake and chronic addiction"
        },
        {
          "entity_type": "Disease",
          "entity_name": "addictions",
          "context": "addictions are similar to other chronic relapsing disorders"
        },
        {
          "entity_type": "Disease",
          "entity_name": "diabetes",
          "context": "such as diabetes, asthma, and hypertension"
        },
        {
          "entity_type": "Disease",
          "entity_name": "asthma",
          "context": "such as diabetes, asthma, and hypertension"
        },
        {
          "entity_type": "Disease",
          "entity_name": "hypertension",
          "context": "such as diabetes, asthma, and hypertension"
        }
      ]
    },
    {
      "chunk_id": "00e9e77dc350fa2caaf0fb13c8d339a8",
      "entities": [
        {
          "entity_type": "Disease",
          "entity_name": "Addiction",
          "context": "Addiction can be conceptualised as a three-stage, recurring cycle"
        },
        {
          "entity_type": "Effect",
          "entity_name": "intoxication",
          "context": "binge/intoxication"
        },
        {
          "entity_type": "Effect",
          "entity_name": "negative affect",
          "context": "withdrawal/negative affect"
        },
        {
          "entity_type": "Effect",
          "entity_name": "craving",
          "context": "preoccupation/anticipation (craving)"
        },
        {
          "entity_type": "Effect",
          "entity_name": "neuroplastic changes",
          "context": "involves neuroplastic changes in the brain"
        },
        {
          "entity_type": "Disease",
          "entity_name": "stress",
          "context": "brain reward, stress, and executive function systems"
        },
        {
          "entity_type": "Disease",
          "entity_name": "addiction",
          "context": "neurobiology of addiction"
        },
        {
          "entity_type": "Effect",
          "entity_name": "impulsivity",
          "context": "A definition of impulsivity is"
        },
        {
          "entity_type": "Effect",
          "entity_name": "compulsivity",
          "context": "A definition of compulsivity is the manifestation of"
        },
        {
          "entity_type": "Effect",
          "entity_name": "pleasure",
          "context": "accompanied by feelings of pleasure or gratification"
        },
        {
          "entity_type": "Effect",
          "entity_name": "gratification",
          "context": "feelings of pleasure or gratification"
        },
        {
          "entity_type": "Disease",
          "entity_name": "obsessive-compulsive disorder",
          "context": "disorders such as obsessive-compulsive disorder"
        },
        {
          "entity_type": "Effect",
          "entity_name": "tension",
          "context": "reduce tension or anxiety"
        },
        {
          "entity_type": "Effect",
          "entity_name": "anxiety",
          "context": "reduce tension or anxiety from obsessive thoughts"
        },
        {
          "entity_type": "Effect",
          "entity_name": "obsessive thoughts",
          "context": "anxiety from obsessive thoughts"
        },
        {
          "entity_type": "Effect",
          "entity_name": "impulsivity",
          "context": "move from impulsivity to compulsivity"
        },
        {
          "entity_type": "Effect",
          "entity_name": "compulsivity",
          "context": "move from impulsivity to compulsivity"
        },
        {
          "entity_type": "Effect",
          "entity_name": "positive reinforcement",
          "context": "shifts from positive to negative reinforcement"
        },
        {
          "entity_type": "Effect",
          "entity_name": "negative reinforcement",
          "context": "shifts from positive to negative reinforcement"
        },
        {
          "entity_type": "Effect",
          "entity_name": "impulsivity",
          "context": "impulsivity and compulsivity can coexist"
        },
        {
          "entity_type": "Effect",
          "entity_name": "compulsivity",
          "context": "impulsivity and compulsivity can coexist"
        },
        {
          "entity_type": "Disease",
          "entity_name": "addiction",
          "context": "stages of the addiction cycle"
        }
      ]
    },
    {
      "chunk_id": "9435414e08901ff381166960ba4cec71",
      "entities": [
        {
          "entity_type": "Disease",
          "entity_name": "addiction",
          "context": "neurobiology of addiction"
        },
        {
          "entity_type": "Disease",
          "entity_name": "addiction",
          "context": "individuals with addiction"
        },
        {
          "entity_type": "Disease",
          "entity_name": "addiction",
          "context": "animal model of addiction"
        },
        {
          "entity_type": "Disease",
          "entity_name": "psychopathological condition",
          "context": "associated with the psychopathological condition"
        }
      ]
    },
    {
      "chunk_id": "6fb86e275a43eac76b72f0341bc6a37d",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "dopamine",
          "context": "mesocorticolimbic dopamine system"
        }
      ]
    },
    {
      "chunk_id": "2e22989c2a2e2186b1bba7f4975ce5cf",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "dopamine",
          "context": "phasic dopamine cell firing"
        },
        {
          "entity_type": "Compound",
          "entity_name": "dopamine D1 receptors",
          "context": "activation of dopamine D1 receptors"
        },
        {
          "entity_type": "Effect",
          "entity_name": "conditioning",
          "context": "necessary for conditioning to occur"
        }
      ]
    },
    {
      "chunk_id": "a64d9885d1beef4197755f3cfe1be8db",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "glutamate",
          "context": "involve glutamate-modulated"
        },
        {
          "entity_type": "Compound",
          "entity_name": "N-methyl-D-aspartate",
          "context": "N-methyl-D-aspartate (NMDA) receptors"
        },
        {
          "entity_type": "Compound",
          "entity_name": "NMDA",
          "context": "N-methyl-D-aspartate (NMDA) receptors"
        },
        {
          "entity_type": "Compound",
          "entity_name": "\\alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid",
          "context": "\\alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors"
        },
        {
          "entity_type": "Compound",
          "entity_name": "AMPA",
          "context": "\\alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors"
        }
      ]
    },
    {
      "chunk_id": "0b3e16296e87fb2a8ba80211edd49ed1",
      "entities": [
        {
          "entity_type": "Disease",
          "entity_name": "addiction",
          "context": "progression through the addiction cycle"
        },
        {
          "entity_type": "Effect",
          "entity_name": "craving",
          "context": "intense desire for the drug (ie, craving)"
        },
        {
          "entity_type": "Effect",
          "entity_name": "compulsive use",
          "context": "compulsive use when individuals with addiction"
        },
        {
          "entity_type": "Compound",
          "entity_name": "dopamine",
          "context": "drive dopamine signalling"
        },
        {
          "entity_type": "Effect",
          "entity_name": "pharmacological effects",
          "context": "when its pharmacological effects lessen"
        },
        {
          "entity_type": "Compound",
          "entity_name": "dopamine",
          "context": "tonic dopamine cell firing"
        },
        {
          "entity_type": "Compound",
          "entity_name": "dopamine",
          "context": "stable dopamine levels in the dopamine projections"
        },
        {
          "entity_type": "Compound",
          "entity_name": "D1 receptors",
          "context": "lower-affinity D1 receptors"
        },
        {
          "entity_type": "Compound",
          "entity_name": "cyclic adenosine monophosphate",
          "context": "stimulate cyclic adenosine monophosphate (cAMP) signalling"
        },
        {
          "entity_type": "Compound",
          "entity_name": "cAMP",
          "context": "stimulate cyclic adenosine monophosphate (cAMP) signalling"
        },
        {
          "entity_type": "Effect",
          "entity_name": "drug reward",
          "context": "involved in both acute drug reward"
        },
        {
          "entity_type": "Effect",
          "entity_name": "conditioning",
          "context": "acute drug reward and conditioning"
        },
        {
          "entity_type": "Compound",
          "entity_name": "dopamine",
          "context": "spikes in dopamine release"
        },
        {
          "entity_type": "Compound",
          "entity_name": "D2 receptors",
          "context": "D2 receptors, which inhibit cAMP signalling"
        },
        {
          "entity_type": "Compound",
          "entity_name": "cAMP",
          "context": "inhibit cAMP signalling"
        },
        {
          "entity_type": "Compound",
          "entity_name": "dopamine",
          "context": "stimulated by both phasic and tonic dopamine"
        },
        {
          "entity_type": "Effect",
          "entity_name": "drug reward",
          "context": "not deemed necessary for drug reward"
        },
        {
          "entity_type": "Compound",
          "entity_name": "D3 receptors",
          "context": "D3 receptors, which are high-affinity dopamine receptors"
        },
        {
          "entity_type": "Compound",
          "entity_name": "dopamine receptors",
          "context": "high-affinity dopamine receptors"
        },
        {
          "entity_type": "Compound",
          "entity_name": "D1 receptors",
          "context": "co-localise in the nucleus accumbens with D1 receptors"
        },
        {
          "entity_type": "Effect",
          "entity_name": "drug-seeking behaviour",
          "context": "associated with drug-seeking behaviour"
        }
      ]
    },
    {
      "chunk_id": "79ef615183593ad961fb7fe56524db69",
      "entities": [
        {
          "entity_type": "Effect",
          "entity_name": "withdrawal response",
          "context": "produce[s] the withdrawal response"
        },
        {
          "entity_type": "Compound",
          "entity_name": "dopamine",
          "context": "decreases in dopaminergic and serotonergic transmission"
        },
        {
          "entity_type": "Compound",
          "entity_name": "serotonin",
          "context": "decreases in dopaminergic and serotonergic transmission"
        },
        {
          "entity_type": "Compound",
          "entity_name": "amphetamine",
          "context": "amphetamine-induced"
        },
        {
          "entity_type": "Compound",
          "entity_name": "methylphenidate",
          "context": "methylphenidate-induced"
        },
        {
          "entity_type": "Compound",
          "entity_name": "dopamine",
          "context": "striatal dopamine responses"
        },
        {
          "entity_type": "Effect",
          "entity_name": "rewarding effects",
          "context": "lower self-reports of the drug\u2019s rewarding effects"
        }
      ]
    },
    {
      "chunk_id": "ed1341abb40f0634985929f8c62b6bc8",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "opioid",
          "context": "responsivity during opioid withdrawal"
        },
        {
          "entity_type": "Compound",
          "entity_name": "gamma-aminobutyric acid",
          "context": "decreases in GABAergic and increases in NMDA glutamatergic transmission"
        },
        {
          "entity_type": "Compound",
          "entity_name": "N-methyl-D-aspartate",
          "context": "decreases in GABAergic and increases in NMDA glutamatergic transmission"
        },
        {
          "entity_type": "Compound",
          "entity_name": "glutamate",
          "context": "decreases in GABAergic and increases in NMDA glutamatergic transmission"
        },
        {
          "entity_type": "Compound",
          "entity_name": "nicotine",
          "context": "nicotinic receptor function in the nucleus accumbens and ventral tegmental area in nicotine"
        },
        {
          "entity_type": "Compound",
          "entity_name": "ethanol",
          "context": "nicotine, alcohol, and other addictions"
        },
        {
          "entity_type": "Disease",
          "entity_name": "opioid withdrawal",
          "context": "responsivity during opioid withdrawal"
        },
        {
          "entity_type": "Disease",
          "entity_name": "addictions",
          "context": "nicotine, alcohol, and other addictions"
        },
        {
          "entity_type": "Disease",
          "entity_name": "acute withdrawal",
          "context": "clinical syndrome of acute withdrawal"
        },
        {
          "entity_type": "Disease",
          "entity_name": "protracted abstinence",
          "context": "protracted abstinence"
        },
        {
          "entity_type": "Effect",
          "entity_name": "decreases in GABAergic transmission",
          "context": "decreases in GABAergic and increases in NMDA glutamatergic transmission"
        },
        {
          "entity_type": "Effect",
          "entity_name": "increases in NMDA glutamatergic transmission",
          "context": "decreases in GABAergic and increases in NMDA glutamatergic transmission"
        },
        {
          "entity_type": "Effect",
          "entity_name": "decreases in reward system function",
          "context": "Such decreases in reward system function"
        },
        {
          "entity_type": "Effect",
          "entity_name": "loss of interest in normal, non-drug rewards",
          "context": "explain the loss of interest in normal, non-drug rewards"
        },
        {
          "entity_type": "Effect",
          "entity_name": "narrowing of the behavioural repertoire toward drugs and drug-related stimuli",
          "context": "narrowing of the behavioural repertoire toward drugs and drug-related stimuli"
        }
      ]
    },
    {
      "chunk_id": "2ef4beb34b0f74bdf90852f85ddacdfc",
      "entities": [
        {
          "entity_type": "Effect",
          "entity_name": "positive rewarding effects",
          "context": "positive rewarding effects of drugs of abuse"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Corticotropin-releasing factor (CRF)",
          "context": "brain stress system mediated by CRF"
        },
        {
          "entity_type": "Effect",
          "entity_name": "dysregulated",
          "context": "CRF are dysregulated"
        },
        {
          "entity_type": "Disease",
          "entity_name": "dependence",
          "context": "drugs with dependence or abuse potential"
        },
        {
          "entity_type": "Disease",
          "entity_name": "abuse potential",
          "context": "drugs with dependence or abuse potential"
        },
        {
          "entity_type": "Effect",
          "entity_name": "elevated",
          "context": "common response of elevated adrenocorticotropin hormone"
        },
        {
          "entity_type": "Compound",
          "entity_name": "adrenocorticotropin hormone",
          "context": "elevated adrenocorticotropin hormone"
        },
        {
          "entity_type": "Compound",
          "entity_name": "corticosterone",
          "context": "elevated adrenocorticotropin hormone, corticosterone"
        },
        {
          "entity_type": "Effect",
          "entity_name": "acute withdrawal",
          "context": "during acute withdrawal"
        },
        {
          "entity_type": "Effect",
          "entity_name": "tolerance",
          "context": "As tolerance and withdrawal develop"
        },
        {
          "entity_type": "Effect",
          "entity_name": "withdrawal",
          "context": "tolerance and withdrawal develop"
        },
        {
          "entity_type": "Compound",
          "entity_name": "norepinephrine",
          "context": "brain stress systems, such as CRF, norepinephrine"
        },
        {
          "entity_type": "Compound",
          "entity_name": "dynorphin",
          "context": "norepinephrine, and dynorphin"
        },
        {
          "entity_type": "Effect",
          "entity_name": "negative emotional states",
          "context": "development of negative emotional states"
        },
        {
          "entity_type": "Effect",
          "entity_name": "protracted abstinence",
          "context": "in withdrawal and protracted abstinence"
        },
        {
          "entity_type": "Effect",
          "entity_name": "anti-reward",
          "context": "concept of anti-reward was developed"
        },
        {
          "entity_type": "Effect",
          "entity_name": "limit reward",
          "context": "act to limit reward"
        },
        {
          "entity_type": "Compound",
          "entity_name": "CRF receptor antagonists",
          "context": "CRF receptor antagonists block"
        },
        {
          "entity_type": "Effect",
          "entity_name": "anxiety-like effects",
          "context": "anxiety-like, stress-like effects of drug withdrawal"
        },
        {
          "entity_type": "Effect",
          "entity_name": "stress-like effects",
          "context": "stress-like effects of drug withdrawal"
        },
        {
          "entity_type": "Effect",
          "entity_name": "drug withdrawal",
          "context": "effects of drug withdrawal"
        },
        {
          "entity_type": "Effect",
          "entity_name": "excessive drug taking",
          "context": "excessive drug taking during compulsive drug seeking"
        },
        {
          "entity_type": "Effect",
          "entity_name": "compulsive drug seeking",
          "context": "compulsive drug seeking in animals"
        },
        {
          "entity_type": "Compound",
          "entity_name": "kappa opioid receptor antagonists",
          "context": "kappa opioid receptor antagonists, when injected"
        },
        {
          "entity_type": "Compound",
          "entity_name": "dopamine",
          "context": "release of dopamine in the nucleus accumbens"
        },
        {
          "entity_type": "Compound",
          "entity_name": "kappa opioid receptor",
          "context": "dynorphin-kappa opioid receptor system"
        },
        {
          "entity_type": "Effect",
          "entity_name": "negative emotional state",
          "context": "contributes to the negative emotional state"
        }
      ]
    },
    {
      "chunk_id": "7b46deac105ce4cbe1e27f2b852f7863",
      "entities": [
        {
          "entity_type": "Disease",
          "entity_name": "relapse",
          "context": "key element of relapse in humans"
        },
        {
          "entity_type": "Disease",
          "entity_name": "addiction",
          "context": "defines addiction as a chronic relapsing disorder"
        },
        {
          "entity_type": "Effect",
          "entity_name": "craving",
          "context": "linked to the construct of craving"
        },
        {
          "entity_type": "Disease",
          "entity_name": "relapse",
          "context": "correlate with relapse"
        },
        {
          "entity_type": "Disease",
          "entity_name": "relapse",
          "context": "neurobiological mechanisms of relapse"
        }
      ]
    },
    {
      "chunk_id": "fc19f43d25dd35e56e31d77cdb318902",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "Glutamate",
          "context": "sends glutamatergic projections"
        },
        {
          "entity_type": "Compound",
          "entity_name": "dopamine",
          "context": "mesocortical dopamine neurons"
        },
        {
          "entity_type": "Effect",
          "entity_name": "excitatory control",
          "context": "exerting excitatory control over dopamine cell firing"
        },
        {
          "entity_type": "Effect",
          "entity_name": "dopamine cell firing",
          "context": "control over dopamine cell firing"
        },
        {
          "entity_type": "Compound",
          "entity_name": "dopamine",
          "context": "dopamine release in the prefrontal cortex"
        },
        {
          "entity_type": "Effect",
          "entity_name": "dopamine release",
          "context": "dopamine release in the prefrontal cortex"
        }
      ]
    },
    {
      "chunk_id": "940f726dafbcc35a15478328cba01865",
      "entities": [
        {
          "entity_type": "Effect",
          "entity_name": "drug-induced reinstatement",
          "context": "drug-induced reinstatement is mediated"
        },
        {
          "entity_type": "Compound",
          "entity_name": "glutamate",
          "context": "a glutamatergic projection"
        },
        {
          "entity_type": "Compound",
          "entity_name": "dopamine",
          "context": "modulated by dopamine activity"
        },
        {
          "entity_type": "Compound",
          "entity_name": "D_1 receptor",
          "context": "through D_1 and D_2 receptors"
        },
        {
          "entity_type": "Compound",
          "entity_name": "D_2 receptor",
          "context": "through D_1 and D_2 receptors"
        },
        {
          "entity_type": "Effect",
          "entity_name": "Cue-induced reinstatement",
          "context": "Cue-induced reinstatement also involves"
        },
        {
          "entity_type": "Effect",
          "entity_name": "stress-induced reinstatement",
          "context": "the stress-induced reinstatement of drug-related responding"
        },
        {
          "entity_type": "Compound",
          "entity_name": "CRF",
          "context": "activation of both CRF and norepinephrine"
        },
        {
          "entity_type": "Compound",
          "entity_name": "norepinephrine",
          "context": "activation of both CRF and norepinephrine"
        },
        {
          "entity_type": "Disease",
          "entity_name": "alcohol dependence",
          "context": "alcohol dependence models"
        },
        {
          "entity_type": "Effect",
          "entity_name": "craving-like responses",
          "context": "mediates craving-like responses"
        }
      ]
    },
    {
      "chunk_id": "418ba8d682ec5d56bc3cce5eac5749a2",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "\u0394FosB",
          "context": "accumulating levels of \u0394FosB"
        },
        {
          "entity_type": "Effect",
          "entity_name": "rewarding effects",
          "context": "sensitivity to the rewarding effects of drugs of abuse"
        },
        {
          "entity_type": "Compound",
          "entity_name": "drugs of abuse",
          "context": "rewarding effects of drugs of abuse"
        },
        {
          "entity_type": "Disease",
          "entity_name": "addiction",
          "context": "maintain a state of addiction"
        },
        {
          "entity_type": "Compound",
          "entity_name": "cocaine",
          "context": "repeated cocaine exposure"
        },
        {
          "entity_type": "Effect",
          "entity_name": "histone modifications",
          "context": "leads to histone modifications"
        },
        {
          "entity_type": "Effect",
          "entity_name": "pre-mRNA splicing",
          "context": "alter pre-mRNA splicing"
        },
        {
          "entity_type": "Effect",
          "entity_name": "conditioned place preference",
          "context": "cocaine-induced conditioned place preference"
        }
      ]
    },
    {
      "chunk_id": "035c2766f6375060a630490f5e495c03",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "cocaine",
          "context": "cue-induced cocaine seeking"
        },
        {
          "entity_type": "Effect",
          "entity_name": "cue-induced cocaine seeking",
          "context": "risk of cue-induced cocaine seeking"
        },
        {
          "entity_type": "Effect",
          "entity_name": "incubation of craving",
          "context": "cocaine seeking (incubation of craving)"
        },
        {
          "entity_type": "Effect",
          "entity_name": "prolonged withdrawal",
          "context": "during prolonged withdrawal"
        },
        {
          "entity_type": "Effect",
          "entity_name": "protracted abstinence",
          "context": "withdrawal (protracted abstinence in humans)"
        },
        {
          "entity_type": "Disease",
          "entity_name": "relapse",
          "context": "vulnerability to relapse"
        }
      ]
    },
    {
      "chunk_id": "0d67099d6924894261d2a7f489ca3156",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "fatty acid amide hydrolase",
          "context": "gene for fatty acid amide hydrolase"
        },
        {
          "entity_type": "Compound",
          "entity_name": "fatty acid amide hydrolase",
          "context": "reduction of fatty acid amide hydrolase expression"
        },
        {
          "entity_type": "Effect",
          "entity_name": "reduction of fatty acid amide hydrolase expression",
          "context": "presented a reduction of fatty acid amide hydrolase expression"
        },
        {
          "entity_type": "Effect",
          "entity_name": "enhanced fronto-amygdala connectivity",
          "context": "selectively enhanced fronto-amygdala connectivity"
        },
        {
          "entity_type": "Effect",
          "entity_name": "fear extinction learning",
          "context": "enhanced ... fear extinction learning"
        },
        {
          "entity_type": "Effect",
          "entity_name": "decreased anxiety-like behaviours",
          "context": "decreased anxiety-like behaviours"
        },
        {
          "entity_type": "Effect",
          "entity_name": "neuroplasticity",
          "context": "target for neuroplasticity"
        }
      ]
    },
    {
      "chunk_id": "7d6c567cb85e77dd56d34f4c8dee3aaf",
      "entities": [
        {
          "entity_type": "Disease",
          "entity_name": "addiction",
          "context": "process of addiction"
        },
        {
          "entity_type": "Compound",
          "entity_name": "drugs",
          "context": "risk for drug use"
        },
        {
          "entity_type": "Disease",
          "entity_name": "substance use disorder",
          "context": "risk of a substance use disorder"
        },
        {
          "entity_type": "Compound",
          "entity_name": "drugs",
          "context": "experiment with legal and illegal drugs"
        },
        {
          "entity_type": "Compound",
          "entity_name": "alcohol",
          "context": "Heavy alcohol use"
        },
        {
          "entity_type": "Disease",
          "entity_name": "neurobehavioural sequelae",
          "context": "range of neurobehavioural sequelae"
        },
        {
          "entity_type": "Disease",
          "entity_name": "impairments in visuospatial processing",
          "context": "impairments in visuospatial processing"
        },
        {
          "entity_type": "Disease",
          "entity_name": "impairments in attention",
          "context": "impairments in visuospatial processing, attention, and memory"
        },
        {
          "entity_type": "Disease",
          "entity_name": "impairments in memory",
          "context": "impairments in visuospatial processing, attention, and memory"
        }
      ]
    },
    {
      "chunk_id": "4c6ecb606841d8b82f6ab1d389a917b8",
      "entities": [
        {
          "entity_type": "Disease",
          "entity_name": "mental disorders",
          "context": "manual of mental disorders"
        },
        {
          "entity_type": "Disease",
          "entity_name": "Addiction",
          "context": "Addiction and the brain"
        },
        {
          "entity_type": "Disease",
          "entity_name": "Drug dependence",
          "context": "Drug dependence, a chronic medical illness"
        },
        {
          "entity_type": "Disease",
          "entity_name": "medical illness",
          "context": "a chronic medical illness"
        },
        {
          "entity_type": "Disease",
          "entity_name": "Drug abuse",
          "context": "Drug abuse: hedonic homeostatic dysregulation"
        },
        {
          "entity_type": "Disease",
          "entity_name": "Drug addiction",
          "context": "Drug addiction and its underlying neurobiological basis"
        },
        {
          "entity_type": "Disease",
          "entity_name": "impulsivity",
          "context": "aspects of impulsivity"
        },
        {
          "entity_type": "Disease",
          "entity_name": "Compulsivity",
          "context": "Compulsivity, impulsivity, and the DSM-5 process"
        },
        {
          "entity_type": "Disease",
          "entity_name": "impulsivity",
          "context": "Compulsivity, impulsivity, and the DSM-5 process"
        },
        {
          "entity_type": "Disease",
          "entity_name": "addiction",
          "context": "Neurocircuitry of addiction"
        },
        {
          "entity_type": "Disease",
          "entity_name": "drug addiction",
          "context": "animal models of drug addiction and alcoholism"
        },
        {
          "entity_type": "Disease",
          "entity_name": "alcoholism",
          "context": "drug addiction and alcoholism"
        },
        {
          "entity_type": "Disease",
          "entity_name": "psychiatric disorders",
          "context": "Animal models of psychiatric disorders"
        },
        {
          "entity_type": "Disease",
          "entity_name": "Drug addiction",
          "context": "Drug addiction, dysregulation of reward"
        },
        {
          "entity_type": "Disease",
          "entity_name": "addiction",
          "context": "dark side of addiction"
        },
        {
          "entity_type": "Disease",
          "entity_name": "addiction",
          "context": "prefrontal cortex in addiction"
        },
        {
          "entity_type": "Disease",
          "entity_name": "addiction",
          "context": "habits and addiction"
        },
        {
          "entity_type": "Compound",
          "entity_name": "opioid",
          "context": "endogenous opioid release"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Serotonin",
          "context": "Serotonin at the nexus of impulsivity"
        },
        {
          "entity_type": "Compound",
          "entity_name": "cocaine",
          "context": "reactivity in cocaine addiction"
        },
        {
          "entity_type": "Disease",
          "entity_name": "impulsivity",
          "context": "nexus of impulsivity and cue reactivity"
        },
        {
          "entity_type": "Disease",
          "entity_name": "cocaine addiction",
          "context": "reactivity in cocaine addiction"
        }
      ]
    },
    {
      "chunk_id": "2344a7af08388ec1b1616eb0d56aeb7c",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "GABAA receptor drugs",
          "context": "GABAA receptor drugs and neuronal plasticity"
        },
        {
          "entity_type": "Effect",
          "entity_name": "neuronal plasticity",
          "context": "GABAA receptor drugs and neuronal plasticity"
        },
        {
          "entity_type": "Effect",
          "entity_name": "reward",
          "context": "plasticity in reward and aversion"
        },
        {
          "entity_type": "Effect",
          "entity_name": "aversion",
          "context": "plasticity in reward and aversion"
        },
        {
          "entity_type": "Compound",
          "entity_name": "nicotine",
          "context": "aspects of nicotine abuse"
        },
        {
          "entity_type": "Disease",
          "entity_name": "nicotine abuse",
          "context": "aspects of nicotine abuse"
        },
        {
          "entity_type": "Disease",
          "entity_name": "Addiction",
          "context": "Addiction as a stress surfeit disorder"
        },
        {
          "entity_type": "Disease",
          "entity_name": "stress surfeit disorder",
          "context": "Addiction as a stress surfeit disorder"
        },
        {
          "entity_type": "Effect",
          "entity_name": "gene transfer",
          "context": "Herpes simplex virus-mediated gene transfer"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Noradrenaline",
          "context": "Noradrenaline in the ventral forebrain"
        },
        {
          "entity_type": "Disease",
          "entity_name": "opiate withdrawal-induced aversion",
          "context": "critical for opiate withdrawal-induced aversion"
        },
        {
          "entity_type": "Effect",
          "entity_name": "arousal",
          "context": "Addiction and arousal"
        },
        {
          "entity_type": "Compound",
          "entity_name": "hypocretin",
          "context": "the hypocretin connection"
        },
        {
          "entity_type": "Compound",
          "entity_name": "RP 67580",
          "context": "RP 67580, a selective antagonist"
        },
        {
          "entity_type": "Compound",
          "entity_name": "neurokinin-1 receptors",
          "context": "antagonist of neurokinin-1 receptors"
        },
        {
          "entity_type": "Compound",
          "entity_name": "naloxone",
          "context": "modifies some of the naloxone-precipitated"
        },
        {
          "entity_type": "Compound",
          "entity_name": "morphine",
          "context": "naloxone-precipitated morphine withdrawal signs"
        },
        {
          "entity_type": "Disease",
          "entity_name": "morphine withdrawal signs",
          "context": "morphine withdrawal signs in rats"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Amphetamine",
          "context": "Amphetamine-induced dopamine release"
        },
        {
          "entity_type": "Compound",
          "entity_name": "dopamine",
          "context": "Amphetamine-induced dopamine release"
        },
        {
          "entity_type": "Compound",
          "entity_name": "cocaine",
          "context": "blunted in cocaine dependence"
        },
        {
          "entity_type": "Disease",
          "entity_name": "cocaine dependence",
          "context": "blunted in cocaine dependence"
        },
        {
          "entity_type": "Effect",
          "entity_name": "self-administer cocaine",
          "context": "choice to self-administer cocaine"
        },
        {
          "entity_type": "Effect",
          "entity_name": "opioid receptor-dependent signaling",
          "context": "opioid receptor-dependent signaling and behavior"
        },
        {
          "entity_type": "Effect",
          "entity_name": "behavior",
          "context": "signaling and behavior"
        },
        {
          "entity_type": "Compound",
          "entity_name": "neuropeptide Y (NPY)",
          "context": "Brain neuropeptide Y (NPY) in stress"
        },
        {
          "entity_type": "Disease",
          "entity_name": "stress",
          "context": "Y (NPY) in stress and alcohol dependence"
        },
        {
          "entity_type": "Disease",
          "entity_name": "alcohol dependence",
          "context": "stress and alcohol dependence"
        },
        {
          "entity_type": "Compound",
          "entity_name": "NOP receptors",
          "context": "Activation of brain NOP receptors"
        },
        {
          "entity_type": "Disease",
          "entity_name": "alcohol withdrawal symptoms",
          "context": "attenuates acute and protracted alcohol withdrawal symptoms"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Endocannabinoid",
          "context": "Endocannabinoid-mediated synaptic plasticity"
        },
        {
          "entity_type": "Effect",
          "entity_name": "synaptic plasticity",
          "context": "Endocannabinoid-mediated synaptic plasticity"
        },
        {
          "entity_type": "Disease",
          "entity_name": "addiction-related behavior",
          "context": "plasticity and addiction-related behavior"
        },
        {
          "entity_type": "Compound",
          "entity_name": "oxytocin",
          "context": "Role of oxytocin in the neuroadaptation"
        },
        {
          "entity_type": "Compound",
          "entity_name": "drugs of abuse",
          "context": "neuroadaptation to drugs of abuse"
        },
        {
          "entity_type": "Disease",
          "entity_name": "drugs of abuse",
          "context": "neuroadaptation to drugs of abuse"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Cocaine",
          "context": "Cocaine cue-induced dopamine release"
        },
        {
          "entity_type": "Compound",
          "entity_name": "dopamine",
          "context": "Cocaine cue-induced dopamine release"
        },
        {
          "entity_type": "Disease",
          "entity_name": "cocaine dependent participants",
          "context": "study in cocaine dependent participants"
        },
        {
          "entity_type": "Compound",
          "entity_name": "glutamate",
          "context": "The glutamate homeostasis hypothesis"
        },
        {
          "entity_type": "Disease",
          "entity_name": "addiction",
          "context": "hypothesis of addiction"
        },
        {
          "entity_type": "Compound",
          "entity_name": "heroin",
          "context": "relapse to heroin and cocaine seeking"
        },
        {
          "entity_type": "Compound",
          "entity_name": "cocaine",
          "context": "relapse to heroin and cocaine seeking"
        },
        {
          "entity_type": "Disease",
          "entity_name": "relapse to heroin and cocaine seeking",
          "context": "Neurobiology of relapse to heroin and cocaine seeking"
        },
        {
          "entity_type": "Compound",
          "entity_name": "dopamine",
          "context": "mesocorticolimbic\u2014dopamine in reward"
        },
        {
          "entity_type": "Effect",
          "entity_name": "reward",
          "context": "dopamine in reward and addiction"
        },
        {
          "entity_type": "Disease",
          "entity_name": "addiction",
          "context": "dopamine in reward and addiction"
        },
        {
          "entity_type": "Compound",
          "entity_name": "dopamine",
          "context": "decreases in dopamine release"
        },
        {
          "entity_type": "Disease",
          "entity_name": "alcoholics",
          "context": "detoxified alcoholics"
        },
        {
          "entity_type": "Disease",
          "entity_name": "addicted human brain",
          "context": "The addicted human brain"
        },
        {
          "entity_type": "Compound",
          "entity_name": "cocaine",
          "context": "self-administration of cocaine"
        },
        {
          "entity_type": "Compound",
          "entity_name": "dopamine D1 receptor",
          "context": "dopamine D1 receptor knock-out mice"
        },
        {
          "entity_type": "Effect",
          "entity_name": "self-administration of cocaine",
          "context": "Lack of self-administration of cocaine"
        },
        {
          "entity_type": "Effect",
          "entity_name": "NMDAR-dependent burst firing",
          "context": "Disruption of NMDAR-dependent burst firing"
        },
        {
          "entity_type": "Compound",
          "entity_name": "dopamine",
          "context": "firing by dopamine neurons"
        },
        {
          "entity_type": "Effect",
          "entity_name": "phasic dopamine-dependent behavior",
          "context": "assessment of phasic dopamine-dependent behavior"
        },
        {
          "entity_type": "Compound",
          "entity_name": "D2-like dopamine receptor antagonists",
          "context": "The affinity of D2-like dopamine receptor antagonists"
        },
        {
          "entity_type": "Compound",
          "entity_name": "cocaine",
          "context": "effect on cocaine self-administration"
        },
        {
          "entity_type": "Effect",
          "entity_name": "cocaine self-administration",
          "context": "effect on cocaine self-administration"
        }
      ]
    },
    {
      "chunk_id": "7f3cf68c752e078385afee549546b9fd",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "dopamine D2-like receptors",
          "context": "Role of dopamine D2-like receptors"
        },
        {
          "entity_type": "Compound",
          "entity_name": "cocaine",
          "context": "in cocaine self-administration"
        },
        {
          "entity_type": "Compound",
          "entity_name": "D2 receptor antagonists",
          "context": "novel D2 receptor antagonists"
        },
        {
          "entity_type": "Effect",
          "entity_name": "cocaine self-administration",
          "context": "in cocaine self-administration"
        },
        {
          "entity_type": "Compound",
          "entity_name": "D2R",
          "context": "D2R striatopallidal neurons"
        },
        {
          "entity_type": "Effect",
          "entity_name": "inhibit locomotor and drug reward processes",
          "context": "inhibit both locomotor and drug reward processes"
        },
        {
          "entity_type": "Compound",
          "entity_name": "dopamine",
          "context": "Illicit dopamine transients"
        },
        {
          "entity_type": "Effect",
          "entity_name": "actions of abused drugs",
          "context": "actions of abused drugs"
        },
        {
          "entity_type": "Effect",
          "entity_name": "Drug-evoked synaptic plasticity",
          "context": "Drug-evoked synaptic plasticity in addiction"
        },
        {
          "entity_type": "Disease",
          "entity_name": "addiction",
          "context": "synaptic plasticity in addiction"
        },
        {
          "entity_type": "Compound",
          "entity_name": "VTA DA",
          "context": "Co-activation of VTA DA and GABA neurons"
        },
        {
          "entity_type": "Compound",
          "entity_name": "GABA",
          "context": "Co-activation of VTA DA and GABA neurons"
        },
        {
          "entity_type": "Compound",
          "entity_name": "nicotine",
          "context": "mediates nicotine reinforcement"
        },
        {
          "entity_type": "Effect",
          "entity_name": "nicotine reinforcement",
          "context": "mediates nicotine reinforcement"
        },
        {
          "entity_type": "Disease",
          "entity_name": "addiction",
          "context": "understanding of addiction"
        },
        {
          "entity_type": "Compound",
          "entity_name": "AMPA receptor",
          "context": "AMPA receptor plasticity"
        },
        {
          "entity_type": "Effect",
          "entity_name": "AMPA receptor plasticity",
          "context": "AMPA receptor plasticity in the nucleus accumbens"
        },
        {
          "entity_type": "Compound",
          "entity_name": "cocaine",
          "context": "exposure to cocaine"
        },
        {
          "entity_type": "Compound",
          "entity_name": "VTA CRF",
          "context": "VTA CRF neurons"
        },
        {
          "entity_type": "Compound",
          "entity_name": "nicotine",
          "context": "effects of nicotine withdrawal"
        },
        {
          "entity_type": "Effect",
          "entity_name": "aversive effects",
          "context": "mediate the aversive effects of nicotine withdrawal"
        },
        {
          "entity_type": "Disease",
          "entity_name": "nicotine withdrawal",
          "context": "effects of nicotine withdrawal"
        },
        {
          "entity_type": "Effect",
          "entity_name": "intake escalation",
          "context": "promote intake escalation"
        },
        {
          "entity_type": "Compound",
          "entity_name": "\u03b15 nicotinic receptor subunit",
          "context": "Habenular \u03b15 nicotinic receptor subunit signalling"
        },
        {
          "entity_type": "Compound",
          "entity_name": "nicotine",
          "context": "controls nicotine intake"
        },
        {
          "entity_type": "Effect",
          "entity_name": "controls nicotine intake",
          "context": "signalling controls nicotine intake"
        },
        {
          "entity_type": "Compound",
          "entity_name": "NPY",
          "context": "The NPY system"
        },
        {
          "entity_type": "Disease",
          "entity_name": "stress",
          "context": "NPY system in stress"
        },
        {
          "entity_type": "Disease",
          "entity_name": "anxiety",
          "context": "stress, anxiety and depression"
        },
        {
          "entity_type": "Disease",
          "entity_name": "depression",
          "context": "stress, anxiety and depression"
        },
        {
          "entity_type": "Compound",
          "entity_name": "alcohol",
          "context": "during alcohol withdrawal"
        },
        {
          "entity_type": "Disease",
          "entity_name": "alcohol withdrawal",
          "context": "during alcohol withdrawal"
        },
        {
          "entity_type": "Disease",
          "entity_name": "cognitive impairment",
          "context": "predicts cognitive impairment"
        },
        {
          "entity_type": "Effect",
          "entity_name": "excessive alcohol drinking",
          "context": "excessive alcohol drinking"
        },
        {
          "entity_type": "Compound",
          "entity_name": "cocaine",
          "context": "Relapse to cocaine-seeking"
        },
        {
          "entity_type": "Effect",
          "entity_name": "Relapse to cocaine-seeking",
          "context": "Relapse to cocaine-seeking"
        },
        {
          "entity_type": "Disease",
          "entity_name": "Psychomotor stimulant addiction",
          "context": "Psychomotor stimulant addiction"
        },
        {
          "entity_type": "Effect",
          "entity_name": "drug relapse",
          "context": "model of drug relapse"
        },
        {
          "entity_type": "Disease",
          "entity_name": "addiction",
          "context": "hidden island of addiction"
        },
        {
          "entity_type": "Compound",
          "entity_name": "psychomotor stimulant drugs",
          "context": "effects of psychomotor stimulant drugs"
        },
        {
          "entity_type": "Effect",
          "entity_name": "reward-enhancing effects",
          "context": "reward-enhancing and stereotypical effects"
        },
        {
          "entity_type": "Effect",
          "entity_name": "stereotypical effects",
          "context": "stereotypical effects of psychomotor stimulant drugs"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Calcium",
          "context": "Calcium signalling remodelling"
        },
        {
          "entity_type": "Effect",
          "entity_name": "Calcium signalling remodelling",
          "context": "Calcium signalling remodelling and disease"
        },
        {
          "entity_type": "Disease",
          "entity_name": "disease",
          "context": "remodelling and disease"
        },
        {
          "entity_type": "Effect",
          "entity_name": "reward",
          "context": "prediction and reward"
        },
        {
          "entity_type": "Compound",
          "entity_name": "cocaine",
          "context": "Single cocaine exposure"
        },
        {
          "entity_type": "Effect",
          "entity_name": "long-term potentiation",
          "context": "induces long-term potentiation in dopamine neurons"
        },
        {
          "entity_type": "Compound",
          "entity_name": "dopamine",
          "context": "in dopamine neurons"
        },
        {
          "entity_type": "Compound",
          "entity_name": "cocaine",
          "context": "Cocaine seeking habits"
        },
        {
          "entity_type": "Effect",
          "entity_name": "Cocaine seeking habits",
          "context": "Cocaine seeking habits"
        },
        {
          "entity_type": "Compound",
          "entity_name": "dopamine",
          "context": "dopamine-dependent serial connectivity"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Dopamine",
          "context": "Dopamine operates as a subsecond modulator"
        },
        {
          "entity_type": "Effect",
          "entity_name": "modulator of food seeking",
          "context": "modulator of food seeking"
        },
        {
          "entity_type": "Compound",
          "entity_name": "dopamine",
          "context": "Stimulant-induced dopamine increases"
        },
        {
          "entity_type": "Effect",
          "entity_name": "Stimulant-induced dopamine increases",
          "context": "Stimulant-induced dopamine increases"
        },
        {
          "entity_type": "Compound",
          "entity_name": "cocaine",
          "context": "active cocaine abusers"
        },
        {
          "entity_type": "Compound",
          "entity_name": "dopamine",
          "context": "model of dopamine system regulation"
        },
        {
          "entity_type": "Compound",
          "entity_name": "alcohol",
          "context": "understanding alcohol and psychostimulant craving"
        },
        {
          "entity_type": "Compound",
          "entity_name": "psychostimulant",
          "context": "alcohol and psychostimulant craving"
        },
        {
          "entity_type": "Effect",
          "entity_name": "craving",
          "context": "psychostimulant craving"
        },
        {
          "entity_type": "Disease",
          "entity_name": "Addiction",
          "context": "craving. Addiction"
        }
      ]
    },
    {
      "chunk_id": "ea47a37babe30b8c7f911b045f90af14",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "cocaine",
          "context": "high and craving during cocaine self-administration"
        },
        {
          "entity_type": "Effect",
          "entity_name": "high",
          "context": "Neural correlates of high and craving"
        },
        {
          "entity_type": "Effect",
          "entity_name": "craving",
          "context": "Neural correlates of high and craving"
        },
        {
          "entity_type": "Effect",
          "entity_name": "cocaine self-administration",
          "context": "during cocaine self-administration"
        },
        {
          "entity_type": "Compound",
          "entity_name": "methylphenidate",
          "context": "Activation of orbital and medial prefrontal cortex by methylphenidate"
        },
        {
          "entity_type": "Compound",
          "entity_name": "cocaine",
          "context": "methylphenidate in cocaine-addicted subjects"
        },
        {
          "entity_type": "Disease",
          "entity_name": "addiction",
          "context": "relevance to addiction"
        },
        {
          "entity_type": "Disease",
          "entity_name": "cocaine-addicted subjects",
          "context": "methylphenidate in cocaine-addicted subjects"
        },
        {
          "entity_type": "Effect",
          "entity_name": "drug cues",
          "context": "Neural reactivity to drug cues"
        },
        {
          "entity_type": "Disease",
          "entity_name": "addiction",
          "context": "drug cues in addiction"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Cocaine",
          "context": "Cocaine cues and dopamine in dorsal striatum"
        },
        {
          "entity_type": "Compound",
          "entity_name": "dopamine",
          "context": "Cocaine cues and dopamine in dorsal striatum"
        },
        {
          "entity_type": "Effect",
          "entity_name": "craving",
          "context": "mechanism of craving in cocaine addiction"
        },
        {
          "entity_type": "Disease",
          "entity_name": "cocaine addiction",
          "context": "craving in cocaine addiction"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Cocaine",
          "context": "Cocaine cue-induced dopamine release"
        },
        {
          "entity_type": "Compound",
          "entity_name": "dopamine",
          "context": "Cocaine cue-induced dopamine release"
        },
        {
          "entity_type": "Compound",
          "entity_name": "methylphenidate",
          "context": "Association of methylphenidate-induced craving"
        },
        {
          "entity_type": "Effect",
          "entity_name": "craving",
          "context": "methylphenidate-induced craving"
        },
        {
          "entity_type": "Compound",
          "entity_name": "cocaine",
          "context": "metabolism in cocaine abusers"
        },
        {
          "entity_type": "Disease",
          "entity_name": "cocaine abusers",
          "context": "metabolism in cocaine abusers"
        },
        {
          "entity_type": "Disease",
          "entity_name": "addiction",
          "context": "implications in addiction"
        },
        {
          "entity_type": "Compound",
          "entity_name": "dopamine",
          "context": "Addiction: beyond dopamine reward circuitry"
        },
        {
          "entity_type": "Disease",
          "entity_name": "Addiction",
          "context": "Addiction: beyond dopamine reward circuitry"
        },
        {
          "entity_type": "Disease",
          "entity_name": "alcohol relapse",
          "context": "time to alcohol relapse"
        },
        {
          "entity_type": "Effect",
          "entity_name": "cocaine craving",
          "context": "cue-induced cocaine craving"
        },
        {
          "entity_type": "Compound",
          "entity_name": "cocaine",
          "context": "cue-induced cocaine craving"
        },
        {
          "entity_type": "Effect",
          "entity_name": "food-craving",
          "context": "food-craving activation during fMRI"
        },
        {
          "entity_type": "Effect",
          "entity_name": "cigarette cravings",
          "context": "abstinence-induced cigarette cravings"
        },
        {
          "entity_type": "Disease",
          "entity_name": "chronic smokers",
          "context": "cigarette cravings in chronic smokers"
        },
        {
          "entity_type": "Disease",
          "entity_name": "addiction to cigarette smoking",
          "context": "disrupts addiction to cigarette smoking"
        },
        {
          "entity_type": "Disease",
          "entity_name": "cocaine-dependent subjects",
          "context": "moral judgment in cocaine-dependent subjects"
        },
        {
          "entity_type": "Compound",
          "entity_name": "corticotropin-releasing factor 1 and 2 receptors",
          "context": "localization of corticotropin-releasing factor 1 and 2 receptors"
        },
        {
          "entity_type": "Effect",
          "entity_name": "craving",
          "context": "cue reactivity and craving"
        },
        {
          "entity_type": "Disease",
          "entity_name": "problem gamblers",
          "context": "abstinent problem gamblers"
        },
        {
          "entity_type": "Disease",
          "entity_name": "heavy smokers",
          "context": "heavy smokers and healthy controls"
        },
        {
          "entity_type": "Effect",
          "entity_name": "smoking cues",
          "context": "Brain reactivity to smoking cues"
        },
        {
          "entity_type": "Effect",
          "entity_name": "tobacco abstinence",
          "context": "maintain tobacco abstinence"
        },
        {
          "entity_type": "Disease",
          "entity_name": "Addiction",
          "context": "Addiction, a disease of compulsion and drive"
        },
        {
          "entity_type": "Disease",
          "entity_name": "Addiction",
          "context": "Overlapping neuronal circuits in addiction and obesity"
        },
        {
          "entity_type": "Disease",
          "entity_name": "obesity",
          "context": "addiction and obesity"
        },
        {
          "entity_type": "Compound",
          "entity_name": "dopamine",
          "context": "Imaging dopamine's role in drug abuse and addiction"
        },
        {
          "entity_type": "Disease",
          "entity_name": "drug abuse",
          "context": "dopamine's role in drug abuse and addiction"
        },
        {
          "entity_type": "Disease",
          "entity_name": "addiction",
          "context": "drug abuse and addiction"
        },
        {
          "entity_type": "Compound",
          "entity_name": "dopamine D2 receptor",
          "context": "Decreased dopamine D2 receptor availability"
        },
        {
          "entity_type": "Compound",
          "entity_name": "cocaine",
          "context": "frontal metabolism in cocaine abusers"
        },
        {
          "entity_type": "Disease",
          "entity_name": "cocaine abusers",
          "context": "frontal metabolism in cocaine abusers"
        }
      ]
    },
    {
      "chunk_id": "dd50a9cec21af15aece220760126aacd",
      "entities": [
        {
          "entity_type": "Disease",
          "entity_name": "addiction",
          "context": "neurobiological basis of addiction"
        },
        {
          "entity_type": "Effect",
          "entity_name": "Action inhibition",
          "context": "'Action inhibition Emotion control' is associated with vmPFC"
        },
        {
          "entity_type": "Effect",
          "entity_name": "Emotion control",
          "context": "'Action inhibition Emotion control' is associated with vmPFC"
        },
        {
          "entity_type": "Effect",
          "entity_name": "Affective state",
          "context": "resulting 'Affective state', 'Stress', and 'Incentive to action'"
        },
        {
          "entity_type": "Disease",
          "entity_name": "Stress",
          "context": "resulting 'Affective state', 'Stress', and 'Incentive to action'"
        },
        {
          "entity_type": "Disease",
          "entity_name": "addiction",
          "context": "relevant to the addiction process"
        }
      ]
    },
    {
      "chunk_id": "e60a046523b2c5fffebe05dfa9c6b416",
      "entities": [
        {
          "entity_type": "Disease",
          "entity_name": "addiction",
          "context": "relevant to the addiction process"
        }
      ]
    },
    {
      "chunk_id": "e0db66b38d58fb644154fa6eb5980ad7",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "Glutamate",
          "context": "Glutamate Ventral tegmental area"
        },
        {
          "entity_type": "Compound",
          "entity_name": "gamma-aminobutyric acid",
          "context": "gamma-aminobutyric acid Dorsal striatum"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Dopamine",
          "context": "Dopamine Dorsal striatum"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Glutamate",
          "context": "Glutamate Withdrawal/negative affect"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Corticotropin-releasing factor",
          "context": "Corticotropin-releasing factor Central nucleus of amygdala"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Corticotropin-releasing factor",
          "context": "Corticotropin-releasing factor BNST"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Norepinephrine",
          "context": "Norepinephrine Nucleus accumbens shell"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Dynorphin",
          "context": "Dynorphin Habenula"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Acetylcholine",
          "context": "Acetylcholine Central nucleus of amygdala"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Neuropeptide Y",
          "context": "Neuropeptide Y Central nucleus of amygdala"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Endocannabinoids",
          "context": "Endocannabinoids Preoccupation/anticipation"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Glutamate",
          "context": "Glutamate Prefrontal cortex"
        },
        {
          "entity_type": "Compound",
          "entity_name": "gamma-aminobutyric acid",
          "context": "gamma-aminobutyric acid Hippocampus"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Glutamate",
          "context": "Glutamate Basolateral amygdala"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Glutamate",
          "context": "Glutamate BNST"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Corticotropin-releasing factor",
          "context": "Corticotropin-releasing factor BNST"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Norepinephrine",
          "context": "Norepinephrine Insula"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Corticotropin-releasing factor",
          "context": "Corticotropin-releasing factor"
        },
        {
          "entity_type": "Effect",
          "entity_name": "Binge/intoxication",
          "context": "Neurotransmitter Binge/intoxication Ventral tegmental area"
        },
        {
          "entity_type": "Effect",
          "entity_name": "Withdrawal/negative affect",
          "context": "Glutamate Withdrawal/negative affect Ventral tegmental area"
        },
        {
          "entity_type": "Effect",
          "entity_name": "Preoccupation/anticipation",
          "context": "Endocannabinoids Preoccupation/anticipation Prefrontal cortex"
        }
      ]
    }
  ],
  "total_entities": 381,
  "extraction_date": "2026-02-01T08:53:09.867085+00:00"
}